Foghorn Therapeutics (FHTX) Retained Earnings (2019 - 2026)

Foghorn Therapeutics' Retained Earnings history runs 8 years deep, the most recent figure standing at -$133000.0 for Q1 2026.

• In Q1 2026, Retained Earnings fell 1050.0% year-over-year to -$133000.0; the TTM figure through Mar 2026 stood at -$133000.0 (down 1050.0% YoY), while the FY2025 annual figure was $24000.0, down 100.0% from the prior year.
• Retained Earnings for Q1 2026 stood at -$133000.0, down from $24000.0 in the prior quarter.
• The five-year high for Retained Earnings was $512.5 million in Q4 2024, with the low at -$610.8 million in Q3 2025.
• The 5-year median for Retained Earnings is -$2.9 million (2023), against an average of -$86.9 million.
• The sharpest annual moves came in 2022 and 2023: Retained Earnings surged 242.75% in 2022, then plunged 13481.06% in 2023.
• Foghorn Therapeutics' Retained Earnings stood at $377.2 million in 2022, then gained by 4.76% to $395.2 million in 2023, then gained by 29.69% to $512.5 million in 2024, then slumped by 100.0% to $24000.0 in 2025, then slumped by 654.17% to -$133000.0 in 2026.
• Business Quant data shows FHTX's Retained Earnings at -$133000.0 in Q1 2026, $24000.0 in Q4 2025, and -$610.8 million in Q3 2025.